Dialysis world news


Rays notes: Rhymes debuts at 3B for injured Longoria - Chicago Tribune
ST. PETERSBURG —

IF Will Rhymes, called up from Triple-A Durham on Tuesday, made his first career start at third base for the Tampa Bay Rays on Wednesday as manager Joe Maddon set in motion the parade of players who will fill in while 3B Evan Longoria is out with a partially torn left hamstring.

IF Elliot Johnson started at third base Tuesday. Maddon said he will also use IF Jeff Keppinger. SS Sean Rodriguez and C Chris Gimenez also could find themselves playing there, but those would be game-in-progress moves.

Maddon said he is not auditioning someone for a full-time role.

"It's possible to pick somebody, but I really would anticipate it's going to be a revolving door," Maddon said. "It's just going to be based on our information and on that particular night who appears to be the best matchup."

Maddon was asked about CF B.J. Upton, who has played 63 games at third base; and 2B/RF Ben Zobrist, who has played four. Maddon said neither will be involved in the rotation.

Rhymes, who arrived from Durham during the middle of Tuesday's win, played second base with the Tigers in 2010 and 2011. He became a utility infielder during spring training.

"That was part of the appeal of coming here," Rhymes said. "They were going to let me move around and play some different positions. It's pretty cool to get that opportunity, that they trust me enough to put me out there."

Maddon said Rhymes handled the transition to third base during spring training, and Rhymes said he took ground balls there every day while with Durham. The one thing he didn't work on at Durham was the shifts.

"You lose Longoria and that's horrible for the team, and I'm not trying to fill his shoes at all, but if I can do anything to help them win a game or two here or there, that's all I'm trying to do," Rhymes said.

Farnsworth update

RHP Kyle Farnsworth (right elbow soreness), who was moved to the 60-day disabled list Tuesday, began a throwing program that same afternoon with 25 throws into a tube sock and said his elbow was pain free.

Farnsworth said being moved to the 60-day DL was not a setback since he was told when he went on the DL on Opening Day that he wouldn't be back until mid-June.

"I wasn't going try and rush anything, anyhow," he said. "I'm still going to let my arm tell me what I'm able to do. It would be nice to have a certain date to be ready. I don't want to say I want to be ready by this date, cut and dry. I don't want to do that, just be ready when my arm says I'm ready."

With RHP Fernando Rodney perfect in eight save opportunities, Farnsworth's role as closer may be taken when he returns. He said that won't be a problem.

"No, not at all. We're all in it to win the World Series, so whatever Joe has me do, I've said that since Day One, wherever he has me pitch that's when I'm going to go and I'll go out and do the best I can," Farnsworth said.

Zim to have dialysis

Senior adviser Don Zimmer, 81, underwent a procedure Wednesday to have a shunt inserted so he can undergo dialysis.

Zimmer has not been with the team since the first weekend of the season. He did not attend the 100th anniversary ceremony at Fenway Park and has been in and out of the hospital several times in the past month.

Noteworthy

Wednesday's attendance at Tropicana Field was 9,837. The first three days of the Seattle series has drawn 29,267. Today's finale has a 1:10 p.m. start. ... RF Matt Joyce tripled and homered while batting third Tuesday for the first time this season. He did not hit a triple or homer in his 22 games batting third last season. His three triples this season lead the AL and match his career-high. ... Tuesday's win was the 10th in team history in which the Rays had three hits or less. ... The "Players and Pooches" calendar goes on sale Friday for $15. Proceeds benefit the Pet Pal Animal Shelter in St. Pete.

...

 
Nephrology group agrees to pay $4.3 to settle case - Kingsport Times News

Nephrology group agrees to pay $4.3 to settle case



 

KNOXVILLE, Tenn. (AP) — A Knoxville medical group and its affiliated dialysis clinics have agreed to pay $4.3 million to settle claims that they fraudulently billed the state and federal governments.

An investigation found that Apex Medical Group, which operates under the name of Nephrology Associates, submitted numerous false and fraudulent claims for payment to government health care programs, such as Medicare and TennCare. The U.S. attorney's office in Knoxville said Thursday that the company engaged in a pattern of overbilling for physician services from 2001 to 2006.

The investigation also found that six dialysis clinics owned by Extracorporeal Technologies Inc. and Fort Sanders Kidney Center also improperly billed the government.

As part of the settlement, Apex agreed to be in a five-year integrity program with the federal government.

To comment, you must register and verify your email address by telephone.

Comments are the sole responsibility of the registered user participating in online discussions. You agree not to post comments off topic, abusive, obscene, defamatory, vulgar, threatening or an invasion of privacy. Violators may be banned.

Click here to review our complete user agreement.

...

 
BioTrends Announces a New Syndicated Report Series Entitled LaunchTrends®: Omontys - EON: Enhanced Online News (press release)

EXTON, Pa.--(EON: Enhanced Online News)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, announces a new syndicated report series entitled LaunchTrends: Omontys. Omontys (peginesatide) is a new once-monthly erythropoiesis-stimulating agent (ESA) for anemia due to chronic kidney disease (CKD) in adult patients on dialysis. LaunchTrends: Omontyssurveys will be fielded at one month, three months, six months and twelve months post commercial availability. Each report consists of findings from a quantitative survey with over 75 nephrologists and qualitative interviews (over 15) with a subset of the survey respondents. It is believed that uptake for this product will vary between size of dialysis chains and the hospital settings. Quotas will be implemented to ensure a variety of nephrologists participate in this study.

BioTrends has been following the nephrologists’ perception of Omontys in the TreatmentTrends®: US Nephrology reports since the beginning of 2009. According to the most recent TreatmentTrends survey, almost all nephrologists report a moderate to high interest in Omontys (peginesatide) and they view over 40 percent of their dialysis patients as candidates for treatment.

LaunchTrends: Omontys is a four-wave syndicated report series designed to track physician perception, uptake and the competitive environment of Affymax/Takeda Pharmaceuticals’ Omontys post-commercial availability (announced April 24, 2012). The report will also assess trial and use of Omontys, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages and product satisfaction. The first wave of this report will be published on July 13, 2012.

BioTrends will also track the US uptake of Omontys in the quarterly TreatmentTrends: US Nephrologyreport series with the Q2 2012 report scheduled for release in June 2012. TreatmentTrends: US Nephrology is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

...

 
Limassol police hero promoted - Cyprus Mail

Follow the mail on Twitter.

LIMASSOL police officer, Christos Hadjipavlou, who saved a woman, hooked up to a dialysis machine, from her burning home earlier this week was promoted yesterday to Sergeant in a ceremony at police headquarters.

Hadjipavlou, 31, was promoted on the suggestion of Police Chief Michalis Papageorgiou.

According to police he was promoted because of his ‘altruistic and self-sacrificing act’ when on Tuesday, during the early hours he was the first on the scene of a fire at a residence that started from a multi-socket adaptor in the kitchen.

Hadjipavlou, despite never having been given orders to go inside the house, found a ladder, climbed up to the first-floor window, broke the glass, felt his way through the smoke and found the 48-year-old woman. He unhooked her from the machine then made his way to the window and hung the woman over his knee with her head facing downwards so she would not inhale the smoke. They then waited for the Fire Services to arrive to lower them from the window.

He suffered first degree burns on his left arm as well as being treated for smoke inhalation. The woman’s husband was also treated for smoke inhalation. Her two sons escaped unharmed.

According to police, this was not the first time Hadjipavlou acted above and beyond the call of duty. He has also pulled a man from a burning truck and carried out first aid on a man who had been bitten by a snake.

...

 
Abbott buys potential kidney treatment for $110M - BusinessWeek

NORTH CHICAGO, Ill.

Abbott Laboratories will spend $110 million to buy a potential kidney treatment from the privately held Danish company Action Pharma, the company said Thursday.

The drug, labeled AP214, is in mid-stage clinical testing and is designed to prevent acute kidney injury in patients undergoing major cardiac surgery. The molecule targets systemic inflammation and cellular death caused by a lack of blood flow that can occur during surgery.

Abbott said the deal will improve its pipeline of renal care drugs under development, which includes two potential chronic kidney disease treatments.

Abbott will receive all global rights to develop and sell AP214 to prevent acute kidney injury. It will not make milestone or royalty payments to Action Pharma. Abbott expects to incur a second-quarter charge tied to its payment.

Shares of Abbott climbed 50 cents to $63.15 in afternoon trading, while the Standard and Poor's 500 index fell slightly.


...

 
<< Start < Prev 401 402 403 404 405 406 407 408 409 410 Next > End >>

Page 407 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.